NASDAQ:SLXN Silexion Therapeutics (SLXN) Stock Price, News & Analysis $7.18 +0.38 (+5.59%) Closing price 03:58 PM EasternExtended Trading$6.88 -0.30 (-4.23%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Silexion Therapeutics Stock (NASDAQ:SLXN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Silexion Therapeutics alerts:Sign Up Key Stats Today's Range$6.66▼$7.2350-Day Range$6.80▼$14.9452-Week Range$6.51▼$236.25Volume26,166 shsAverage Volume149,656 shsMarket Capitalization$4.16 millionP/E RatioN/ADividend YieldN/APrice Target$75.00Consensus RatingBuy Company Overview Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. Read More Silexion Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreSLXN MarketRank™: Silexion Therapeutics scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSilexion Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSilexion Therapeutics has received no research coverage in the past 90 days.Read more about Silexion Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioSilexion Therapeutics has a P/B Ratio of 34.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Silexion Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for SLXN. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSilexion Therapeutics does not currently pay a dividend.Dividend GrowthSilexion Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for SLXN. News and Social Media2.6 / 5News Sentiment0.67 News SentimentSilexion Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Silexion Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for SLXN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Silexion Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Silexion Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.00% of the stock of Silexion Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 10.95% of the stock of Silexion Therapeutics is held by institutions.Read more about Silexion Therapeutics' insider trading history. Receive SLXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLXN Stock News HeadlinesSilexion Therapeutics Executes Reverse Stock Split2 hours ago | msn.comSilexion Therapeutics Increases Authorized Share CapitalAugust 19 at 10:31 AM | tipranks.comElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation. You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth.August 22 at 2:00 AM | Paradigm Press (Ad)Silexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 13, 2025 | finanznachrichten.deSilexion Therapeutics Corp. Reports Second Quarter 2025 Financial Results and Preclinical Advancements in RNAi Therapies for KRAS-Driven CancersAugust 12, 2025 | quiverquant.comQSilexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | globenewswire.comSilexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross ProceedsJuly 31, 2025 | globenewswire.comSilexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS MutationJuly 31, 2025 | globenewswire.comSee More Headlines SLXN Stock Analysis - Frequently Asked Questions How have SLXN shares performed this year? Silexion Therapeutics' stock was trading at $30.15 at the beginning of the year. Since then, SLXN shares have decreased by 76.2% and is now trading at $7.18. How were Silexion Therapeutics' earnings last quarter? Silexion Therapeutics Corp (NASDAQ:SLXN) posted its quarterly earnings results on Tuesday, August, 12th. The company reported ($4.32) earnings per share for the quarter, missing the consensus estimate of ($3.15) by $1.17. When did Silexion Therapeutics' stock split? Shares of Silexion Therapeutics reverse split on Sunday, July 27th 2025.The 1-15 reverse split was announced on Sunday, July 27th 2025. The number of shares owned by shareholders was adjusted after the market closes on Sunday, July 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Silexion Therapeutics? Shares of SLXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silexion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silexion Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU). Company Calendar Last Earnings8/12/2025Today8/22/2025Next Earnings (Estimated)9/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLXN Previous SymbolNASDAQ:SLXN CIK2022416 Websilexion.com Phone972-2-674-3430Fax212-572-6395EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Silexion Therapeutics$75.00 High Price Target$75.00 Low Price Target$75.00 Potential Upside/Downside+944.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.44 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-355.74% Debt Debt-to-Equity Ratio26.58 Current Ratio2.44 Quick Ratio2.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book34.19Miscellaneous Outstanding Shares580,000Free Float545,000Market Cap$4.16 million OptionableN/A Beta0.08 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:SLXN) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.